Kalaris Therapeutics, Inc. Common Stock (KLRS)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Kalaris Therapeutics, Inc. Common Stock (KLRS) is listed on Nasdaq, where it has traded since March 19, 2025.
- Listed On
- Nasdaq
- Listed Since
- March 19, 2025
- Employees
- 20
- Market Cap
- $48M
About Kalaris Therapeutics, Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 55 institutions reported holding KLRS, with 18.0 million shares worth $73.4 million in aggregate. The largest reported holder was Samsara Biocapital, with 12.9 million shares worth $52.4 million. Of the 5 largest holders listed below, 1 added shares, 1 reduced its position and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Samsara Biocapital | 12,881,175 | $52M | Reduced 0.52% |
| Rtw Investments | 1,300,000 | $5M | Unchanged |
| Alyeska Investment Group | 572,687 | $2M | Unchanged |
| Vanguard | 465,616 | $2M | Added 59.03% |
| Siren | 435,798 | $2M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is KLRS?
Kalaris Therapeutics, Inc. Common Stock (KLRS) is listed on Nasdaq, where it has traded since March 19, 2025.
Who are the largest institutional holders of KLRS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of KLRS were Samsara Biocapital, Rtw Investments and Alyeska Investment Group.
How many institutions own KLRS?
55 institutions reported a position in KLRS for the quarter ended June 30, 2026, worth $73.4 million in total.
Did institutions buy or sell KLRS last quarter?
Of the 5 largest reported holders, 1 added shares, 1 reduced its position and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for KLRS.
Every reported institutional holder, plus insider and congressional trades in KLRS, on SentiSense.